亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

濟南惠誠醫藥科技有限公司  

生產和銷售各類原料藥及其中間體,如:奧利司他、新利司他、利拉列汀、曲格列汀琥珀酸鹽、苯甲酸阿格列汀、卡格列凈半水合物、磷酸奧司他韋、瑞舒伐他汀鈣及其中間體、磷酸肌酸二鈉鹽、阿地溴銨、噻托溴銨一水合物、依替唑侖、丙戊酸鈉、美沙拉嗪、腎上腺素系列等。

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:趙攀峰
  • 電話:0531-68659623
  • 郵件:sales@hc-pharm.com
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > (S)-N-縮水甘油鄰苯二甲酰亞胺
(S)-N-縮水甘油鄰苯二甲酰亞胺
單價 面議對比
詢價 暫無
發貨 山東濟南市付款后3天內
品牌 惠誠
過期 長期有效
更新 2017-07-19 09:59
 
詳細信息

中文名稱: (S)-N-縮水甘油鄰苯二甲酰亞胺

中文同義詞: (S)-N-縮水甘油鄰苯二甲酰亞胺;(S)-N-環氧丙基鄰苯二甲酰亞胺;(S)-(+)-N-(2,3-乙氧基丙基)鄰苯二甲酰亞胺;利伐沙班中間體2;(S)-(+)-N-(2,3-乙氧基丙基)鄰苯二甲酰亞胺,,利伐沙班中間體;(S)-(+)-N-(2,3-環氧丙基)鄰苯二甲酰亞胺;(S)-N-環氧丙基鄰苯二甲酰亞胺, EE: 97.5%;(S)-N-環氧丙基鄰苯二甲酰亞胺, EE

英文名稱: (S)-(+)-GLYCIDYL PHTHALIMIDE

英文同義詞: (S)-2-OXIRANYLMETHYL-ISOINDOLE-1,3-DIONE;(S)-(+)-GLYCIDYL PHTHALIMIDE;(S)-GLYCIDYL PHTHALIMIDE;2-((2S)-OXIRANYLMETHYL)-1H-ISOINDOLE-1,3(2H)-DIONE;(S)-(+)-N-(2,3-Epoxypropyl)phthalimide;(S)-N-Glycidylphthalimide;2-[(2S)-oxiran-2-ylmethyl]-1H-isoindole-1,3(2H)-dione;Rivaroxaban Intermediate 2

CAS: 161596-47-0

分子式: C11H9NO3

分子量: 203.19

相關類別: N-Substituted Maleimides, Succinimides & Phthalimides;N-Substituted Phthalimides;Oxiranes;Simple 3-Membered Ring *pounds;醫藥中間體;芳烴;中間體;利伐沙班中間體;Intermediate of Rivaroxaban;利萘唑酮中間體;抗凝劑利伐沙班中間體;環氧化物

用途:利伐沙班中間體

©2025 濟南惠誠醫藥科技有限公司 版權所有   技術支持:化工網   訪問量:11467  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |